Breaking News
Investing Pro 0
NEW! Get Actionable Insights with InvestingPro+ Try 7 Days Free

Takeda Pharma logs surprise profit, expects earnings to triple this year

Stock MarketsMay 13, 2020 08:31
Saved. See Saved Items.
This article has already been saved in your Saved Items
© Reuters. People walk past the new headquarters of Takeda Pharmaceutical Co in Tokyo

By Rocky Swift

TOKYO (Reuters) - Takeda Pharmaceutical Co (T:4502) booked a surprise operating profit and forecast that income would triple this business year as hefty acquisition costs related to last year's $59 billion Shire takeover recede.

Japan's largest drugmaker said it expects to make 355 billion yen ($3.3 billion) in operating profit for the year to March.

That compares with 100 billion yen for the year just ended - a result that beat its own estimate of a 10 billion yen profit and a consensus prediction of a 12.7 billion yen loss in a Refinitiv poll of 13 analysts.

Due to the COVID-19 crisis, Takeda halted the start of new drug trials except for its investigational plasma-derived therapy for the disease, initially called TAK-888. It formed an alliance of 10 global plasma companies to develop a shared therapy that uses immune cells taken out of the blood from recovered coronavirus patients.

Clinical trials for the group's product, now called CoVIg-19, could be started in June, Takeda said Wednesday.

The Shire acquisition, completed in January 2019, expanded Takeda's pipeline and diversified its global sales, with half now coming from the United States. But it also saddled the drugmaker with a large debt pile.

To pare down debt, Takeda has pledged to dispose of $10 billion worth of non-core assets. It said last month it would sell selected over-the-counter and prescription products to Denmark-based Orifarm Group for about $670 million.

It offloaded $7 billion in assets last year, including operations in the Middle East and Africa and a dry-eye drug sold for $5.3 billion to Novartis, Refinitiv data show.

Takeda is focusing on five key business areas: oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies. The company told investors in November it expected to launch 14 new products through fiscal 2024 that combined would deliver about $10 billion in peak yearly sales.

Ahead of the results, Takeda's shares rose 1.2% versus a 0.5% slide for the broader market.

Takeda Pharma logs surprise profit, expects earnings to triple this year

Related Articles

Allegro trims expectations as inflation bites
Allegro trims expectations as inflation bites By Reuters - May 26, 2022 3

GDANSK (Reuters) - Poland's Allegro on Thursday trimmed its 2022 expectations, with higher inflation seen hitting discretionary consumer spending, but said it was better...

British government to review of Drahi's BT stake
British government to review of Drahi's BT stake By Reuters - May 26, 2022

(Reuters) - The British government said it will use new powers to examine the national security implications of Patrick Drahi, BT Group (LON:BT)'s biggest shareholder, increasing...

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Our Apps
© 2007-2022 Fusion Media Limited. All Rights Reserved.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
  • Sign up for FREE and get:
  • Real-Time Alerts
  • Advanced Portfolio Features
  • Personalized Charts
  • Fully-Synced App
Continue with Google
Sign up with Email